Quantcast

Latest BioMS Medical Corp Stories

2010-05-03 16:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, AB, May 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced its updated corporate strategy. The Company's new strategy will encompass becoming a full service provider in the healthcare industry, whereby BioMS will directly invest in and advise companies on strategy, financing, mergers & acquisitions (M&A), licensing transactions and undertake technology development. The Company also announced it has hired Mr. Nitin...

2010-04-30 11:29:00

Toronto Stock Exchange Symbol: MS EDMONTON, April 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced that the University of Alberta, a major shareholder of the Company, has sold 12,915,365 BioMS Medical shares. Certain employees, officers and directors of BioMS Medical acquired 7,245,000 of the shares sold by the University of Alberta. "We are very pleased that many of our senior management and Board members saw this as an opportunity to purchase these shares,...

2010-03-16 16:10:00

Toronto Stock Exchange Symbol: MS EDMONTON, March 16 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced financial and operational results for the year ended December 31, 2009. "While 2009 was a challenging year for BioMS and our shareholders, we have remained focused on our core mission of investing our financial and management resources in promising opportunities so as to realize shareholder value," said Kevin Giese, President and CEO of BioMS Medical. "Our investment...

2010-03-03 06:30:00

Toronto Stock Exchange Symbol: MS EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered into a services agreement whereby BioMS will assist Spectral, as required, in its commercialization of Toraymyxin(TM), a therapeutic hemoperfusion device for the...

2009-12-17 17:50:00

Toronto Stock Exchange Symbol: MS EDMONTON, Dec. 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS) today provided the following update on corporate developments: Dirucotide Update ----------------- The Company has completed its substantive review of the data from the discontinued late-stage trials for dirucotide, its drug candidate for the treatment of multiple sclerosis (MS). BioMS has decided that it will explore a compassionate access and research program with limited...

2009-12-17 17:45:00

- BioMS Medical makes strategic investment of $12 million in Spectral - TORONTO and EDMONTON, Dec. 17 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) and BioMS Medical Corp. (TSX: MS) today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States. Spectral...

2009-11-12 16:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, Nov. 12 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS) today announced financial and operational results for the three and nine months ended September 30, 2009. During the quarter, the exclusive license and collaboration agreement between BioMS Medical and Eli Lilly and Company (NYSE: LLY) for dirucotide was terminated with the effect that all commercial rights to dirucotide are returned to BioMS. "During the third quarter, the Company made...

2009-10-21 05:30:00

INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Higher volume drives revenue growth Stronger dollar results in improved gross margin Earnings per share increase to $.86 (reported) or $1.20 (pro forma non-GAAP) Full-year 2009 EPS guidance range revised to $3.90 - $4.00 (reported) or $4.30 - $4.40 (pro forma non-GAAP) Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2009. $in millions, except per share data Third...

2009-08-06 16:00:00

PASADENA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2009, compared with a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2008. For the six months ended June 30, 2009, the net loss was $256,000, or $0.02 per share basic and diluted, compared with net loss of $193,000, or $0.01 per share basic...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related